STAT April 25, 2024
Christopher Boerner, 53, took over as the chief executive officer of Bristol Myers Squibb last November, and immediately made a big move: a series of three acquisitions totaling $24 billion that would give BMS a new schizophrenia drug, a targeted cancer medicine, and radiopharmaceuticals used to treat cancer.
On Thursday, Bristol released first quarter earnings and showed the price for those acquisitions. Annual sales for the quarter were $11.9 billion, a 6% increase...
Today's Sponsors
Today's Sponsor